Reuters: Health
Roche's Tecentriq mixed with Avastin helped liver cancer patients live longer, a boost to the Swiss drugmaker's strategy of expanding its late-to-the-game immunotherapy into niche areas not yet dominated by rivals.
Roche pushes late-comer Tecentriq as new liver cancer option
Roche pushes late-comer Tecentriq as new liver cancer option
Reuters: Health
Roche's Tecentriq mixed with Avastin helped liver cancer patients live longer, a boost to the Swiss drugmaker's strategy of expanding its late-to-the-game immunotherapy into niche areas not yet dominated by rivals.
Reuters: Health
Roche's Tecentriq mixed with Avastin helped liver cancer patients live longer, a boost to the Swiss drugmaker's strategy of expanding its late-to-the-game immunotherapy into niche areas not yet dominated by rivals.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment